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LetterComplete Tumor Regression by Liposomal
Bortezomib in a Humanized Mouse Model of
Multiple Myeloma
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R.M.Schiffelers@uu.nl, r.groen@amsterdamumc.nl).Multiple myeloma (MM), the second most com-mon hematological malignancy, is characterizedby clonal proliferation of malignant plasma cellsin the bone marrow (BM).1 Inhibition of the
ubiquitin proteasome system (UPS) has shown to be particularly
useful for the treatment of MM.2 UPS is a protein degradation
system that maintains homeostasis of intracellular proteins.
Inhibition of the UPS results in the accumulation of polyubiqui-
tinated proteins that triggers different types of cellular stress
responses, followed by growth arrest and apoptosis.3 Bortezomib
(Velcade
®
) is the first-in-class proteasome inhibitor available for
the treatment ofMMandmantle cell lymphoma (MCL).4 Despite
encouraging clinical results, the use of bortezomib has been
limited due to off-target adverse effects that lead to serious
toxicities such as peripheral neuropathy. Furthermore, bortezo-
mib has a poor pharmacokinetic profile, that is, large volume of
distribution and rapid blood clearance, minimizing its therapeu-
tic window.4 Moreover, most patients become refractory to
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A drug delivery system could improve the safety and efficacy of
bortezomib. Encapsulation of drugs into nanomedicines can
substantially improve their pharmacokinetic-pharmacodynamic
profiles and reduce toxicity, thereby widening the therapeutic
window.1,6–9 Since, MM causes increased microvessel density in
its bone marrow (BM) lesions,10 we anticipated that as a
consequence, nanomedicines like liposomes can locally accumu-
late and deliver bortezomib through the enhanced permeability
and retention effect.
In the present study, we evaluated circulation kinetics,
biodistribution, and therapeutic efficacy of long circulating
liposomal bortezomib (LCL-BORT) using a human BM-like
scaffold (huBMsc) xenograft mouse model of MM in which a
human-bone mimic is created by osteogenic differentiation of
humanmesenchymal stromal cells on calcium phosphate scaffolds
(Fig. 1A). Using this model, which besides allowing engraftment
of primary MM has previously proven its translational potential
with Daratumumab,11,12 we show that liposomal packaging of
bortezomib improves the circulation kinetics and biodistribution,
resulting in a striking anti-MM efficacy.
Liposomes with an average diameter of 118±1nm with a
polydispersity index (PDI) 0.08±0.04 were prepared and loaded
with bortezomib by a remote loading method using mannitol and
meglumine as entrapping agents.13 The amount of encapsulated
bortezomib was 137.3±4.2mg/mL with a near complete
encapsulation efficiency of 91.5±2.8%.
The in vitro cytotoxic efficacy, evaluated by a luminescence-
based cytotoxicity assays, showed there was a comparable
and concentration dependent cytotoxicity for both Free- and
LCL-BORT with IC50 values of Free-BORT of 2.1nM and
4.7nM and IC50 values for LCL-BORT of 0.42nM and 6.0nM
for theMM.1S and UM9 cell line respectively. Next, we assessed
and compared the circulation times and biodistribution of
LCL-BORT to Free-BORT in the huBMsc xenograft model
engrafted with the MM.1S myeloma cell line. Bortezomib
concentrations in plasma samples collected at different time
points after a single i.v. injection of Free- or LCL-BORT were
determined by LC–MS/MS. The results show marginally
increased retention of the drug in plasma by liposomal
encapsulation (Supplementary Fig. 1A, http://links.lww.com/
HS/A94). Nevertheless, the maximum plasma concentration
(Cmax) and the plasma levels of bortezomib over time (area under
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Figure 1. In vivo efficacy of liposomal bortezomib in MM.1S tumor bearing mice. (A) Flow-chart summarizing the experimental set-up. (B) Experimental
design. Twelve days after MM.1S cell inoculations into 4 separate scaffolds per mouse, animals were randomized based on baseline BLI signals on day 0. Animals
were treated twice weekly for a total of 5 injections (ie, day 0, 3, 7, 10, and 14). BLI was performed on the day of first injection (day 0) followed by once weekly or as
indicated up to day 101 after treatment initiation. (C) Tumor growth curve. BLI images were analyzed to obtain luminescence intensity as counts per min/square
centimeters (cpm/cm2). Percentage tumor growth was calculated relative to day 0. Statistical analysis was performed using nonlinear regression using exponential
growth equation. Free and liposomal bortezomib showed tumor growth reduction at treatment regimen of 0.5mg/kg. Liposomal bortezomib showed a substantial
tumor growth delay as compared to all other treatment groups. The PBS-line stops at day 35, because day 42 includes only two animals (out of four). One animal
was sacrificed on day 21 due to humane end point, and one showed less BLI signal due to improper luciferin injection. Arrows represent treatment days. Data is
presented as mean ± SEM. (D) Bioluminescence images. Bioluminescence imaging (BLI) was performed on indicated days. Mouse 1 from LCL-BORT 0.5mg/kg
group was found dead in the cage on day 21. This doesn’t seem to be due to dose related toxicity as there was no sign of systemic toxicity on day 14 (∼3.8% body
weight gain on day 14 compared to day 10 in this animal).
Deshantri et al Letterthe curve; AUC) were substantially higher in LCL-BORT treated
mice. In fact, the Cmax of bortezomib was 8-fold higher (6048ng/
mL compared to 802ng/mL) and the AUC0-t increased 7-fold
(3886ng/mL compared to 547 ng/ml) for the liposomal2
formulation. Volume of distribution (Vd) was 104.2 and 30.8
L/kg for Free-BORT and LCL-BORT, respectively, showing a
substantial three-fold reduction (Supplementary Fig. 1B, http://
links.lww.com/HS/A94).
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Figure 2. In vivo efficacy of liposomal bortezomib in mice bearing pMM patient-derived xenografts. (A) Experimental design. Six weeks after patient cells
inoculations into 4 separate scaffolds per mouse, animals were randomized based on baseline BLI signals on day 0. Animals were treated twice weekly for a total of
5 injections (ie, day 0, 3, 7, 10, and 14). BLI was performed on the day of first injection (day 0) followed by once weekly up to 8 weeks after treatment initiation. (B)
Tumor growth curve. BLI images were analyzed to obtain luminescence intensity as counts per min/square centimeters (cpm/cm2). Percentage tumor growth was
calculated relative to day 0. Statistical analysis was performed using nonlinear regression using exponential growth equation. Free and liposomal bortezomib
showed tumor growth reduction at treatment regimen of 0.5mg/kg. Liposomal bortezomib showed a great difference in tumor growth delay compared to free drug
and all other treatment groups. Arrows represent treatment days. Data is presented as mean ± SEM. (C) Bioluminescence images. Mice were inoculated with
luciferase marked patient derived cells into the human bone containing scaffolds. Six weeks after tumor cells inoculation, animals were treated with PBS, free
bortezomib and liposomal bortezomib 0.5mg/kg. All treatments were given twice weekly via the tail vein, total of 5 injections. Bioluminescence imaging (BLI) was
performed weekly. BLI images on the right side of the animals are shown.
(2020) 4:5 www.hemaspherejournal.comPreviously, we have shown a long circulatory half-life for
PEGylated liposomes in the huBMsc model, which was in
agreement with the long circulating property of comparable
liposomal formulations in other murine tumor models. Approxi-
mately 35%of the injected dose could still be found 24hours post
injection.14 In the present study, in Free- as well as in LCL-BORT
group, the bortezomib concentrations were considerably lower
already 1hour after injection. These results are in line with
previously reported data on a liposomal formulation of
bortezomib for the treatment of chronic myeloid leukemia that
shows similar pharmacokinetic profiles to our formulation.15
To evaluate the biodistribution of bortezomib, drug concen-
trations were measured in a panel of tissue homogenates
including tumor bearing scaffolds and organs, that is, femur,
sternum, liver, spleen, and brain by LC–MS/MS (Supplementary
Fig. 1C and 1D, http://links.lww.com/HS/A94). In MM.1S
tumor-bearing scaffolds, bortezomib concentrations were slightly
higher in case of LCL-BORT compared to the free drug.
Relatively low bortezomib concentrations were detected in femur
and sternum, which decreased over time in both Free- and LCL-
BORT groups. Interestingly, drug concentrations were higher in3
the scaffolds than in femur and sternum indicating that more
drugs accumulated at the tumor sites.
Next, we evaluated the therapeutic efficacy of liposomal
bortezomib formulation in the huBMsc xenograft model. Twelve
days after inoculation with MM.1S tumor cells, huBMsc-mice
received five injections of either Free-, LCL-BORT or PBS as a
control (twice weekly, i.v.) on day 0, 3, 7, 10, and 14 (day 0
considered to be the first day of injections) (Fig. 1B). Biolumines-
cence imaging (BLI) was used to monitor tumor growth over
time. As expected, significant tumor growth inhibition was seen
in the Free-BORT 0.5mg/kg treated animals. However, only one
of the four animals showed a complete tumor regression 7 days
after the start of treatment. Interestingly, despite a marginal
improvement in the pharmacokinetic profile, complete tumor
regression was seen in all mice of the LCL-BORT 0.5mg/kg
treatment group already after two injections, that is, 7 days after
treatment initiation (Fig. 1C, 1D, and Supplementary Fig. 2,
http://links.lww.com/HS/A94). These results are also reflected by
the tumor doubling time (TDT) analyzed by non-linear
regression. TDT was 3.4 days (95% CI = 3.3–3.6) for the PBS
treated group, 6.1 days (95% CI=5.6–7.3) for the Free-BORT
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group as the tumors experienced complete regressions (Fig. 1C).
Two animals of the LCL-BORT group relapsed on day 42 (ie, 4
weeks after treatments cessation), reached the baseline on day 70
(approximately 113% tumor growth compared to day 0) and
could be monitored till day 101, the point where the tumor
burden reached its humane endpoint. Humane endpoints in all
other groups were reached on or before day 42. These
observations underline a striking improvement in therapeutic
efficacy of liposomal encapsulation of bortezomib. Moreover,
this increase in affectivity was not accompanied by an obvious
increase in toxicity as both treatment groups showed approxi-
mately a 10% body weight reduction. This reduction was,
however, reversible after cessation of the treatments (Supple-
mentary Fig. 3, http://links.lww.com/HS/A94).
Finally, we compared Free- with LCL-BORT using a patient
derived xenograft (PDX) of the huBMsc-model. As indicated
(Fig. 2A), 6 weeks after cells inoculation mice were treated with
PBS, Free- or LCL-BORT at 0.5mg/kg twice weekly (day 0, 3, 7,
10, and 14). Similar to the MM.1S xenografts, both Free-BORT
and LCL-BORT resulted in a significant inhibition of tumor
growth (Fig. 2B). Although the Free-BORT group in this PDX
model also resulted in complete tumor regression in 3 out of 4
animals, they were not long-lasting with relapses starting at 28
days after treatment was started. In contrast, the LCL-BORT
treatment showed complete tumor regression in all mice (Fig. 2B,
2C and Supplementary Fig. 4) that did not relapse till the end of
the experiment. Again, the increase of affectivity was not
accompanied with an increase in toxicity, since comparable
reductions in weight of the mice was observed, which was
partially reversible after treatments were stopped (Supplementary
Fig. 5, http://links.lww.com/HS/A94).
Taken together, liposomal bortezomib outperformed free drug
in both xenograft models tested by remarkably improving
therapeutic efficacy and enhancing the survival of animals.
Although only a marginal improvement in drug accumulation
was seen in tumor-bearing scaffolds and bones, an overall higher
drug exposure and bioavailability was noted in case of liposomal
bortezomib (increasedCmax and AUC) as compared to free
bortezomib, resulting in a 7-fold higher plasma concentration up
to 24hours. This might be key to the difference in the efficacy that
we have observed here. Importantly, in clinical practice
bortezomib is currently given subcutaneously and not intrave-
nously in order to reduce toxicity, mainly peripheral neuropathy,
while maintaining efficacy. This reduction in toxicity has been
attributed to the lower Cmax achieved by the subcutaneous
route.16,17 In this current preclinical study, the higher Cmax for
liposomal bortezomib, however, should not be interpreted as
indicative for an increased potential of peripheral toxicity. The
Cmax of the liposomal formulation is a result of total drug in the
circulation, that is, free bortezomib plus liposomal-encapsulated
bortezomib. At the time of the Cmax the majority of circulating
drug is liposomal-encapsulated and, therefore, not being exposed
to healthy tissues, reducing the chance of systemic toxicity, but
also prevented from rapid clearance, hence, the higher Cmax.
To our knowledge this is the first time that complete
tumor regression is shown by liposomal bortezomib therapy
in a clinically relevant mouse model of multiple myeloma.
Moreover, the results show that liposomal encapsulation of
bortezomib exerts a striking therapeutic efficacy compared to the
free drug. Liposomal bortezomib could be further exploited in
clinical settings for MM treatment and has potential to be4
implemented to the existing treatment regimens, especially for the
frail patients.
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